Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2002 for LecTec Corporation (Note: The request metadata listed "Axogen, Inc.", but the filing text identifies the registrant as LecTec Corporation). The Company manufactures and sells products based on advanced skin interface technologies. In September 2001, the Company changed its fiscal year-end from June 30 to December 31.
Key Financial Metrics
| Metric | Q1 2002 | Q1 2001 |
|---|---|---|
| Net Sales | $1,514,495 | $3,748,560 |
| Gross Profit | $488,351 | $1,013,423 |
| Gross Margin | 32.2% | 27.0% |
| Net Loss | $(806,981) | $(543,781) |
| Loss Per Share (Basic/Diluted) | $(0.20) | $(0.14) |
| Cash and Cash Equivalents (End of Period) | $389,070 | $48,384 |
| Net Cash Used in Operating Activities | $(973,340) | $(791,007) |
| Working Capital | $410,834 | N/A (Fiscal Year Change) |
| Current Ratio | 1.1 | N/A (Fiscal Year Change) |
Debt and Liquidity: The Company has a $2,000,000 asset-based line of credit with no borrowings outstanding as of March 31, 2002. However, the Company is in default of covenants regarding minimum book net worth and maximum loss, rendering the line of credit unavailable until cured or waived. The Company also holds a mortgage with a principal balance due in December 2002.
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 59.6% to $1.51 million. This was driven by an 83.0% drop in conductive and medical tape sales (following the sale of those assets in April 2001) and a 51.2% drop in therapeutic consumer product sales due to weak demand.
- New Product Line: The Company launched "NeoSkin" skin care products in February 2002, generating $292,072 in initial sales.
- Margin Improvement: Despite lower sales, gross margin improved to 32.2% from 27.0% due to a shift in sales mix toward higher-margin branded products.
- Expense Reduction: Operating expenses decreased due to aggressive cost control measures, including reductions in compensation, travel, and promotional expenses.
- Cash Position: Cash and cash equivalents decreased by $1.04 million during the quarter, primarily due to cash used in operating activities.
Outlook, Risks, and Management Commentary
- Financial Outlook: Management expects to continue operating at a net loss and experiencing negative cash flow from operations for the foreseeable future.
- Liquidity Risks: The Company is currently in default on its line of credit covenants. Funding future operations may require additional equity or debt investments, with no assurance such capital will be available.
- Strategic Actions: The Company renegotiated a supply agreement in May 2002 to receive advance payments from a major customer and is exploring factoring receivables and other capital options.
- Restructuring: A restructuring accrual of $38,767 remains related to the wind-down of the conductive business, with completion expected by June 30, 2002.
- Market Risks: Risks include dependence on major customers, competitive pricing pressures, and the need for regulatory approvals.
Investor Verification Checklist
- Verify the status of the covenant default on the $2,000,000 line of credit and whether a waiver has been obtained.
- Confirm the sustainability of the new "NeoSkin" product line sales and its contribution to gross margins.
- Assess the Company's ability to generate positive cash flow given the projected continued net losses.
- Review the terms of the renegotiated supply agreement regarding advance payments from the major customer.
- Monitor the timeline for the completion of the conductive business restructuring and associated costs.